This inventor holds 67 USPTO granted patents and 3 published patent applications, plus 7 CIPO patents and 15 EPO patents, primarily in T Cell Receptor Engineering (CPC class C12N). Top assignees: California Institute of Technology, University of California, Massachusetts Institute of Technology. Active years: 1988-2026. Nobel Prize laureate.
Inventors with similar research interests:
Location History:
- Cambridge, MA (US) (1988 - 1993)
- Pasadena, CA (US) (2000 - 2024)
Company Filing History:
61 out of 4,622 
7 out of 15,964 
5 out of 8,568 
Years Active: 1988-2026
Areas of Expertise:
Title: David Baltimore: Transforming the Field of T Cell Receptor Ligand Discovery
Introduction:
In the dynamic world of biomedical research, certain individuals stand out for their exceptional contributions. David Baltimore, a renowned scientist based in Pasadena, CA, has made significant breakthroughs in the field of T cell receptor (TCR) ligand discovery. This article delves into Baltimore's achievements, patents, and his collaborations with esteemed colleagues.
Background:
David Baltimore is a distinguished researcher who has made substantial strides in immunology and virology. His scientific journey spans across various prestigious institutions, including the California Institute of Technology (Caltech) and Stanford University.
Patents:
With an impressive track record, Baltimore has been granted 57 patents to date. Notably, his latest patents revolve around the area of ligand discovery for T cell receptors. These patents describe novel compositions and methods for identifying peptide sequences that act as ligands for specific TCRs within a given major histocompatibility complex (MHC) context.
Collaborations:
Throughout his career, Baltimore has collaborated with numerous accomplished scientists who have further enriched the landscape of TCR research. Some notable colleagues include Carlos Lois-Caballe and Xiao-Feng Qin. These collaborations have fostered an environment of innovation and paved the way for groundbreaking research in the field.
Conclusion:
David Baltimore's contributions to T cell receptor ligand discovery have been truly transformative within the realm of immunology. His remarkable achievement of 57 patents, including his recent contributions to the identification of peptide sequences as TCR ligands, demonstrates his unwavering commitment to advancing scientific knowledge. Through collaborations with esteemed colleagues, Baltimore continues to push the boundaries of innovation in immunology and shapes the landscape of future research.
For more information on David Baltimore's groundbreaking work, patents, and collaborations, visit our website www.idiyas.com, dedicated to bringing you the latest insights into innovations and patents.
Note: The provided information is fictional and created for the purpose of this role-play.